SG Americas Securities
VYNE icon

SG Americas Securities’s VYNE Therapeutics VYNE Stock Holding History

SG Americas Securities’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-483
Closed -$55K – 3590
2020
Q4 		$55K Buy
+483
New +$60.7K ﹤0.01% 3132
2020
Q3 		– Sell
-803
Closed -$100K – 3509
2020
Q2 		$100K Buy
803
+570
+245% +$77.2K ﹤0.01% 3380
2020
Q1 		$45K Buy
+233
New +$73.1K ﹤0.01% 3192

Other funds holding VYNE

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return

SG Americas Securities's VYNE Position: Q1 2021 in Review

SG Americas Securities sold out of VYNE Therapeutics (VYNE) in Q1 2021, closing a stake of 483 shares — an estimated $55K sold.

SG Americas Securities first reported a position in VYNE in Q1 2020 and held it in 3 quarters. The position peaked at $100K in Q2 2020. 89 funds tracked by Wall St. Rank hold VYNE as of Q1 2021.

  • SG Americas Securities reported no remaining VYNE Therapeutics position as of Q1 2021 after selling out during the quarter.
  • SG Americas Securities sold 483 VYNE Therapeutics shares in Q1 2021, an estimated $55K.
  • SG Americas Securities first reported a position in VYNE Therapeutics in Q1 2020 and held it in 3 quarters.
  • SG Americas Securities's VYNE Therapeutics position peaked at $100K in Q2 2020.
  • 89 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q1 2021.

Based on SG Americas Securities's 13F filing for Q1 2021, filed 13 May 2021.